Altimmune Statistics
Share Statistics
Altimmune has 71.12M shares outstanding. The number of shares has increased by 34.89% in one year.
| Shares Outstanding | 71.12M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.24% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 70.53M |
| Failed to Deliver (FTD) Shares | 33.07K |
| FTD / Avg. Volume | 1.11% |
Short Selling Information
The latest short interest is 22.94M, so 32.25% of the outstanding shares have been sold short.
| Short Interest | 22.94M |
| Short % of Shares Out | 32.25% |
| Short % of Float | 32.52% |
| Short Ratio (days to cover) | 12.57 |
Valuation Ratios
The PE ratio is -6.77 and the forward PE ratio is -6.46.
| PE Ratio | -6.77 |
| Forward PE | -6.46 |
| PS Ratio | 1406.17 |
| Forward PS | 25.6 |
| PB Ratio | 3.09 |
| P/FCF Ratio | -7.9 |
| PEG Ratio | n/a |
Enterprise Valuation
Altimmune Inc. has an Enterprise Value (EV) of 464.54M.
| EV / Earnings | -5.25 |
| EV / Sales | 1090.47 |
| EV / EBITDA | -5.28 |
| EV / EBIT | -4.84 |
| EV / FCF | -6.12 |
Financial Position
The company has a current ratio of 17.26, with a Debt / Equity ratio of 0.
| Current Ratio | 17.26 |
| Quick Ratio | 17.26 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -2740.83 |
Financial Efficiency
Return on equity (ROE) is -0.46% and return on capital (ROIC) is -49.25%.
| Return on Equity (ROE) | -0.46% |
| Return on Assets (ROA) | -0.42% |
| Return on Capital (ROIC) | -49.25% |
| Revenue Per Employee | 7.22K |
| Profits Per Employee | -1.50M |
| Employee Count | 59 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 17.08% in the last 52 weeks. The beta is 0.07, so Altimmune 's price volatility has been higher than the market average.
| Beta | 0.07 |
| 52-Week Price Change | 17.08% |
| 50-Day Moving Average | 7.6 |
| 200-Day Moving Average | 7.51 |
| Relative Strength Index (RSI) | 51.63 |
| Average Volume (20 Days) | 2.99M |
Income Statement
In the last 12 months, Altimmune had revenue of $426.00K and earned -$88.45M in profits. Earnings per share was $-1.66.
| Revenue | 426.00K |
| Gross Profit | -51.00K |
| Operating Income | -95.93M |
| Net Income | -88.45M |
| EBITDA | -87.94M |
| EBIT | -95.93M |
| Earnings Per Share (EPS) | -1.66 |
Balance Sheet
The company has $135.12M in cash and $671.00K in debt, giving a net cash position of $134.45M.
| Cash & Cash Equivalents | 135.12M |
| Total Debt | 671.00K |
| Net Cash | 134.45M |
| Retained Earnings | -466.33M |
| Total Assets | 147.86M |
| Working Capital | 137.12M |
Cash Flow
In the last 12 months, operating cash flow was -$75.81M and capital expenditures -$47.00K, giving a free cash flow of -$75.86M.
| Operating Cash Flow | -75.81M |
| Capital Expenditures | -47.00K |
| Free Cash Flow | -75.86M |
| FCF Per Share | -1.42 |
Margins
Gross margin is -11.97%, with operating and profit margins of -22.52K% and -20.76K%.
| Gross Margin | -11.97% |
| Operating Margin | -22.52K% |
| Pretax Margin | -20.76K% |
| Profit Margin | -20.76K% |
| EBITDA Margin | -20.64K% |
| EBIT Margin | -22.52K% |
| FCF Margin | -17.81K% |
Dividends & Yields
ALT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -18.49% |
| FCF Yield | -11.87% |
Analyst Forecast
The average price target for ALT is $22, which is 145% higher than the current price. The consensus rating is "Buy".
| Price Target | $22 |
| Price Target Difference | 145% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Sep 14, 2018. It was a backward split with a ratio of 1:30.
| Last Split Date | Sep 14, 2018 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | 19.01 |
| Piotroski F-Score | 3 |